Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT vs TACE as Bridge to Transplant in HCC
NCT03960008Phase 3Terminated
- Sponsor
- Lahey Hospital & Medical Center
- Start
- Mar 2020
- Primary completion
- Feb 2024
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Lahey Hospital & Medical Center. Primary endpoint: Duration of Disease Control in Treated Lesions at 1 year. Started Mar 2020; status: terminated.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03960008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960008.